What it's for (Indications)
- Hydrocortisone and fusidic acid topical preparations are primarily indicated for the treatment of inflammatory skin conditions where a bacterial infection is present or highly suspected.
- This combination is particularly effective for dermatoses such as eczema, psoriasis, and various forms of dermatitis (e.
- g.
- , atopic dermatitis, contact dermatitis) that are complicated by secondary bacterial infections caused by susceptible organisms, most commonly *Staphylococcus aureus*.
- The anti-inflammatory action of hydrocortisone helps alleviate symptoms like redness, swelling, and itching, while fusidic acid targets the bacterial component, leading to a more comprehensive treatment approach for infected eczematous lesions or other susceptible inflammatory dermatoses.
- The use should be guided by clinical assessment of bacterial involvement and local antimicrobial susceptibility patterns, if available.
- This combination is not intended for primary bacterial infections without an inflammatory component.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage involves applying a thin film of the cream or ointment to the affected skin area, typically twice daily. The application should be gentle and thorough to ensure adequate coverage without excessive use. Treatment duration should generally be limited, often to no more than 1 to 2 weeks, to minimize the risk of corticosteroid-related adverse effects such as skin atrophy and systemic absorption, as well as to mitigate the development of antibiotic resistance. For pediatric patients, the duration should be as short as possible, and close monitoring for systemic effects is crucial due to their higher skin surface area to body weight ratio and underdeveloped skin barrier. Patients should be advised not to exceed the prescribed frequency or duration of treatment without consulting a healthcare professional, and occlusive dressings should generally be avoided unless specifically directed by a physician. |
Safety & Warnings
Common Side Effects
- Topical application of hydrocortisone and fusidic acid may lead to various side effects, predominantly local cutaneous reactions.
- Common corticosteroid-related effects include burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
- Prolonged use, especially under occlusive dressings or on large surface areas, can increase systemic absorption of hydrocortisone, potentially leading to hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria.
- Fusidic acid may cause local irritation, itching, or rash; rarely, hypersensitivity reactions such as urticaria or angioedema may occur.
- Systemic effects of fusidic acid are rare with topical application.
- If any severe or persistent adverse reactions occur, patients should discontinue use and consult their healthcare provider immediately.
Serious Warnings
- Black Box Warning: This topical combination of hydrocortisone and fusidic acid does not carry a formal FDA Black Box Warning. However, healthcare professionals and patients should be aware of several critical safety considerations due to the corticosteroid and antibiotic components, which warrant careful use and monitoring: 1. **Hypothalamic-Pituitary-Adrenal (HPA) Axis Suppression and Systemic Effects**: Prolonged use, application to large surface areas, occlusive dressings, or use in pediatric patients can lead to significant systemic absorption of hydrocortisone. This may result in reversible HPA axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria. Patients should be monitored for signs of systemic corticosteroid effects, and treatment should be discontinued if these occur. 2. **Antibiotic Resistance**: Inappropriate or prolonged use of fusidic acid can contribute to the development of bacterial resistance, particularly in *Staphylococcus aureus*. Treatment duration should be limited to the shortest effective period, typically no more than 1 to 2 weeks, to minimize this risk and preserve antibiotic efficacy. 3. **Local Skin Reactions and Atrophy**: Continuous, long-term application of corticosteroids, even low-potency ones like hydrocortisone, can cause irreversible skin changes such as atrophy, thinning, striae, telangiectasias, and bruising. These effects are more pronounced on thin skin areas (e.g., face, intertriginous areas) and with occlusive use. 4. **Ophthalmic Effects**: Avoid contact with the eyes. Application near the eyes can lead to increased intraocular pressure, glaucoma, cataracts, and blurred vision, especially with prolonged use. 5. **Masking of Infections**: The anti-inflammatory action of hydrocortisone can mask the clinical signs of untreated infections, potentially allowing them to spread or worsen without clear symptoms. The product should only be used where bacterial infection is confirmed or strongly suspected and susceptible to fusidic acid, and regular clinical review is essential to monitor for treatment effectiveness and adverse events.
- Hydrocortisone and fusidic acid topical preparations should be used with caution.
- Avoid contact with the eyes, as this may lead to irritation, glaucoma, or cataracts with prolonged exposure.
- Application to large surface areas, particularly under occlusive dressings or in areas of skin folds, should be avoided due to the increased risk of systemic absorption and associated adverse effects, including HPA axis suppression.
- Prolonged use, even of low-potency corticosteroids like hydrocortisone, can lead to irreversible skin atrophy, telangiectasias, and striae.
- The corticosteroid component can also mask signs of infection, potentially allowing primary bacterial, fungal, or viral infections to worsen.
- Discontinue use if irritation, sensitization, or superinfection develops.
- Overuse of fusidic acid can contribute to the development of antibiotic resistance.
- Pediatric patients are more susceptible to systemic toxicity due to a larger skin surface area-to-body mass ratio and immature skin barrier function, requiring careful monitoring and limiting treatment duration to the minimum necessary.
- This product is not intended for long-term maintenance therapy.
How it Works (Mechanism of Action)
This combination product leverages two distinct pharmacological actions. Hydrocortisone, a low-potency corticosteroid, exerts its therapeutic effects primarily through anti-inflammatory, antipruritic, and vasoconstrictive mechanisms. It penetrates cell membranes and forms a complex with specific cytoplasmic receptors. This complex then enters the nucleus, binds to DNA, and modifies gene expression, primarily by inhibiting the synthesis of inflammatory mediators such as prostaglandins and leukotrienes via the induction of lipocortins (annexins) that inhibit phospholipase A2. This action reduces capillary permeability and leukocyte migration, thereby alleviating inflammation, erythema, and itching. Fusidic acid is an antibiotic that primarily acts by inhibiting bacterial protein synthesis. It does this by binding to bacterial elongation factor G (EF-G), preventing its dissociation from the ribosome-mRNA complex, thereby blocking translocation and subsequent protein elongation. This mechanism is primarily bacteriostatic but can be bactericidal at higher concentrations. Fusidic acid is particularly effective against Gram-positive bacteria, especially *Staphylococcus aureus*, including some methicillin-resistant strains, making it suitable for treating superficial skin infections.